Trudeau Institute Inc.
Saranac Lake, NY
- UEI
- N6K7XKLGRJ61
- CAGE
- 3R402
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 154 Algonquin Ave, Saranac Lake, NY 12983, USA
- Website
- trudeauinstitute.org
- Founded
- 1884
- Employees
- 51-250
- Estimated annual revenue
- $10M-$50M
- Industry
-
- Consumer Staples
- Food, Beverage & Tobacco
- Food Products
- Agricultural Products
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Probing the novel mechanism of action of tuberculocidal compounds - abstract tuberculosis (TB) is once again the leading… | National Institute of Allergy and Infectious Diseases | $332,414 | |
| Optimization of antitubercular compounds against a novel mycobacterium tuberculosis target, aspc - tuberculosis (TB)… | National Institute of Allergy and Infectious Diseases | $921,320 | |
| Development of a mouse model of tuberculosis that generates human-like pathology - abstract though very few new… | National Institute of Allergy and Infectious Diseases | $841,500 | |
| A novel drug retargeting platform for drug-resistant bacterial infections | National Institute of Allergy and Infectious Diseases | $1,039,500 | |
| Zika virus countermeasures pre-clinical pregnancy models to assess protective efficacy against placental damage and… | Medical Command | $1,286,365 |
About Trudeau Institute Inc.
Trudeau Institute Inc., a tax-exempt non-profit research organization based in Saranac Lake, New York, acts as a prime recipient of federal research grants focused on tuberculosis and infectious disease therapeutics, with ancillary subcontractor support on vaccine development and coronavirus research programs. The institute operates predominantly as a grant recipient (85% of recent awards) under the National Institutes of Health, particularly the National Institute of Allergy and Infectious Diseases (NIAID), with no federal contract prime awards in the source data.
Trudeau's research portfolio centers on tuberculosis drug development and preclinical animal model development for infectious disease therapeutics. Two recent NIAID Project Grants exemplify the scope: a $921,320 grant awarded January 28, 2026, through December 31, 2030, to optimize antitubercular compounds targeting alanine aminotransferase (ASPC), a novel Mycobacterium tuberculosis enzyme, advancing lead compound TI-374 toward clinical viability; and a $332,414 grant awarded February 9, 2026, through January 31, 2028, to characterize tuberculocidal compound TI-507, validating its mechanism against NAD kinase (PPNK) using laboratory and murine infection models. An earlier NIAID grant dated March 1, 2022, through February 29, 2024, supported development of a mouse model of tuberculosis generating human-like pathology, addressing predictive limitations in current preclinical testing. The institute's capability in animal model development and infectious disease research attracts secondary roles on vaccine development programs; Trudeau serves as a sub-recipient under International AIDS Vaccine Initiative prime grants conducting mouse and guinea pig challenge studies for mRNA vaccine candidates (awards dated January 2024 through May 2026), and as a consultant sub-recipient under Columbia University and University of Maryland Baltimore primes on coronavirus vaccine and therapeutic delivery research.
Customer concentration is extreme. NIAID and the broader National Institutes of Health account for 92% of awards by count (39 and 15 awards respectively under the NIH parent entity). The Department of the Navy Bureau of Medicine and Surgery holds a single award with $2.6 million potential value; the Department of the Army Materiel Command holds a $994 thousand award. Awards per year show recent acceleration: one award in 2022, six in 2024, and six in 2026 year-to-date. Only one award faces ultimate completion within the next twenty-four months, creating minimal recompete cliff exposure. Combined obligated dollars ($40.2 million) significantly exceed combined potential value ($3.6 million), reflecting long-duration grants with multi-year funding cycles characteristic of NIH research awards.
Quick answers
What is Trudeau Institute Inc.'s UEI?
Trudeau Institute Inc.'s Unique Entity ID (UEI) in SAM.gov is N6K7XKLGRJ61.
What is Trudeau Institute Inc.'s CAGE code?
Trudeau Institute Inc.'s CAGE code is 3R402.
What is Trudeau Institute Inc.'s primary NAICS code?
Trudeau Institute Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Where is Trudeau Institute Inc. located?
Trudeau Institute Inc.'s physical address in SAM.gov is 154 Algonquin Ave, Saranac Lake, NY 12983, USA.
Is Trudeau Institute Inc. registered in SAM.gov?
Yes. Trudeau Institute Inc.'s SAM.gov registration is active through September 4, 2027.
What is Trudeau Institute Inc.'s most recent federal award?
Trudeau Institute Inc.'s most recent federal grant award is Probing the novel mechanism of action of tuberculocidal compounds - abstract tuberculosis (TB) is once again the leading… (R21AI194706), from National Institute of Allergy and Infectious Diseases, on February 9, 2026.
On GovTribe
See Trudeau Institute Inc.'s full federal record
- Federal contract awards
- IDV awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors